How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)?
Biomarkers and CDx are critical to realising the personalised medicines agenda. They support clinician decision making and are cost efficient for payers. But payers identify challenges around evidence of clinical utility, inconsistent practice between – and within – countries, and question who, ultimately, should pay the biomarker/CDx bill. What can pharma, biomarker and CDx developers learn from these critical insights?
In Biomarkers and Companion Diagnostics: Payer Insights, 10 U.S. and EU5 payers with expertise in product assessment, formulary management and healthcare strategy reveal the touchpoints that impact payer decision making and the ways industry can both meet their needs and achieve successful commercial outcomes.